Kodiak Sciences (NASDAQ:KOD) added ~7% in the premarket on Friday after J.P. Morgan upgraded the eye drug developer, arguing that its experimental therapy KSI-101, which is a bispecific protein ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback